These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 3726073)

  • 21. [Postmarketing surveillance of adverse reactions of drugs].
    Polli EE; Cortellaro M
    Ann Ital Med Int; 1989; 4(1):1-9. PubMed ID: 2702012
    [No Abstract]   [Full Text] [Related]  

  • 22. [Imputability in drug monitoring. Principles of the balanced drug reaction assessment method and principal errors to avoid].
    Lagier G; Vincens M; Castot A
    Therapie; 1983; 38(3):303-18. PubMed ID: 6612667
    [No Abstract]   [Full Text] [Related]  

  • 23. [Comparative organization of drug monitoring in France and 7 European countries].
    Vaissere J; de Cremiers F; Auriche M; Juillet Y
    Therapie; 1986; 41(5):369-74. PubMed ID: 3810527
    [No Abstract]   [Full Text] [Related]  

  • 24. [Critical analysis of the adverse effects reported to the Paris-Fernand Widal Drug Monitoring Center in a 2-month period].
    Castot A; Carlier P; Lagier G; Elmalem J; Vincens M; Efthymiou M
    Therapie; 1986; 41(5):375-7. PubMed ID: 3810528
    [No Abstract]   [Full Text] [Related]  

  • 25. [Drug monitoring].
    Royer RJ
    Bull Soc Ophtalmol Fr; 1985 Nov; Spec No():11-30. PubMed ID: 4064240
    [No Abstract]   [Full Text] [Related]  

  • 26. [Post-marketing surveillance of drugs: epidemiologic approach].
    Stanulović M; Jakovljević V; Sabo A
    Med Pregl; 1987; 40(11-12):573-7. PubMed ID: 3331415
    [No Abstract]   [Full Text] [Related]  

  • 27. [Advantages of a microcomputer system in researching duplicated reports].
    Biour M; Wagniart F; Jablonka J; Hamel JD; Weissenburger J; Cheymol G
    Therapie; 1986; 41(5):383-4. PubMed ID: 3810530
    [No Abstract]   [Full Text] [Related]  

  • 28. Potential role of postmarketing research.
    Venulet J
    Drugs Exp Clin Res; 1987; 13(11):673-83. PubMed ID: 3443043
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of an algorithm to evaluate published reports of adverse drug reactions.
    Case B; Oszko MA
    Am J Hosp Pharm; 1991 Jan; 48(1):121-2. PubMed ID: 2000870
    [No Abstract]   [Full Text] [Related]  

  • 30. [How to assess the risk of drugs?].
    Roujeau JC
    Ann Dermatol Venereol; 1998 Oct; 125(10):673-5. PubMed ID: 9835953
    [No Abstract]   [Full Text] [Related]  

  • 31. How should we react to adverse drug reactions?
    Ferner RE; Beard K
    Postgrad Med J; 2011 Feb; 87(1024):81-2. PubMed ID: 21303818
    [No Abstract]   [Full Text] [Related]  

  • 32. [Microcomputerized data bank of nephrotoxic drugs at the Paris-Saint Antoine Regional Drug Monitoring Center].
    Hamel JD; Biour M; Cheymol G
    Therapie; 1986; 41(5):327-9. PubMed ID: 3810519
    [No Abstract]   [Full Text] [Related]  

  • 33. Adverse drug reactions: a review of relevant factors.
    Ajayi FO; Sun H; Perry J
    J Clin Pharmacol; 2000 Oct; 40(10):1093-101. PubMed ID: 11028248
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Food and Drug Administration monitoring of adverse drug reactions.
    Sills JM; Tanner LA; Milstien JB
    Am J Hosp Pharm; 1986 Nov; 43(11):2764-70. PubMed ID: 3799612
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Information centers on undesirable effects of drugs: also on alerting function].
    Bégaud B; Péré JC; Tubert P; Barat C; Haramburu F; Albin H
    Therapie; 1987; 42(2):231-7. PubMed ID: 3617000
    [No Abstract]   [Full Text] [Related]  

  • 36. International monitoring for adverse drug reactions of long latency.
    Fletcher AP; Griffin JP
    Adverse Drug React Toxicol Rev; 1991; 10(4):209-30. PubMed ID: 1793771
    [No Abstract]   [Full Text] [Related]  

  • 37. Review of Canadian pharmacist involvement in adverse drug reaction reporting.
    Taras-Zasowski KM; Einarson TR
    Can J Hosp Pharm; 1989 Jun; 42(3):105-8, 133. PubMed ID: 10318271
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Revised ADR report permits internal review of drug experience.
    Jeffrey LP
    Pharm Times; 1986 Dec; 52(12):48-50. PubMed ID: 10317827
    [No Abstract]   [Full Text] [Related]  

  • 39. [Minimal information that should be found in reports about suspected adverse reactions of drugs].
    Laporte JR; Lience E
    Med Clin (Barc); 1991 Jun; 97(2):56-7. PubMed ID: 1895784
    [No Abstract]   [Full Text] [Related]  

  • 40. An underrecognized challenge in evaluating postmarketing drug safety.
    Roden DM
    Circulation; 2005 Jan; 111(3):246-8. PubMed ID: 15668350
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.